Rilonacept - CAPS and beyond: A scientific journey

Annals of the New York Academy of Sciences

Volumn 1182, Issue , 2009, Pages 124-134

  Stahl, Neil ^a   Radin, Allen ^a   Mellis, Scott ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Cryopyrin associated periodic syndromes (CAPS); Cytokines; Drug development; Gout; Interleukin 1; Rilonacept

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; COLCHICINE; CRYOPYRIN; GLUCOCORTICOID; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; HYBRID PROTEIN;

ARTHRALGIA; BINDING AFFINITY; CINCA SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CRYOPRIN ASSOCIATED PERIODIC SYNDROME; CYTOKINE PRODUCTION; DIARRHEA; DISEASE ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GOUT; HUMAN; INJECTION SITE REACTION; ISCHIALGIA; LOADING DRUG DOSE; MUCKLE WELLS SYNDROME; NONHUMAN; PATHOGENESIS; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; GENETICS; IMMUNOLOGY; REVIEW;

ANIMALS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; RECOMBINANT FUSION PROTEINS;

EID: 73849143947     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05074.x     Document Type: Conference Paper

References (39)

1. Carpenter, L.R.,G.D.Yancopoulos, N. Stahl. 1998. General mechanisms of cytokine receptor signaling. Adv. Protein Chem. 52: 109-140.
2. Economides, A.N., L.R. Carpenter, J.S. Rudge, et al. 2003. Cytokine traps:multi-component, high-affinity blockers of cytokine action. Nat. Med. 9: 47-52.
3. Dinarello, C.A. 2003. Setting the cytokine trap for autoimmunity. Nat. Med. 9: 20-22.
4. Nixon, R., N. Bansback & A. Brennan. 2007. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: A meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 46: 1140-1147.
5. Garnero, P.,N.Charni,N.Voorznger-Rousselot, et al. 2005. Effects of IL-1 Trap on biochemicalmarkers of inflammation and joint tissue breakdown in patients with rheumatoid arthritis. Arthritis Rheum. 52: S343.
6. Bingham, C.O., M. Genovese, L. Moreland, et al. 2004. Treatment of moderate to severe rheumatoid arthritis with IL-1 Trap [abstract]. Annual Congress of the European League Against Rheumatism. Berlin, Germany. June 9-12, 2004.
7. Bingham, C.O., M.C. Genovese, L.W. Moreland, et al. 2004. Results of a phase II study of IL-1 Trap in moderate to severe rheumatoid arthritis [abstract]. 68th Annual Scientific Meeting of the American College of Rheumatology. San Antonio, TX. October 16-21, 2004.
8. Guler, H.P., J.R. Caldwell, R.M. Fleischman, et al. 2002. Weekly treatment with IL-1 Trap is well tolerated and improved ACR criteria in patients with active rheumatoid arthritis [abstract]. Annual Congress of the European LeagueAgainst Rheumatism. Stockholm, Sweden. June 12-15, 2002.
9. Aksentijevich, I., M. Nowak, M. Mallah, et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46: 3340-3348.
10. Hoffman, H.M., J.L. Mueller, D.H. Broide, et al. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29: 301-305.
11. Feldmann, J., A.M. Prieur, P. Quartier, et al. 2002. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71: 198-203.
12. Hoffman, H.M. 2007. Hereditary immunologic disorders caused by pyrin and cryopyrin. Curr. Allergy Asthma Rep. 7: 323-330.
13. Grateau, G. 2003. Muckle-Wells syndrome. Available at http://www.orpha.net/data/patho/ GB/uk-MWS.pdf. Accessed January 12, 2009.
14. Muckle, T.J. 1979. The 'Muckle-Wells' syndrome. Br. J. Dermatol. 100: 87-92.
15. Hoffman, H.M. 2003. Familial cold antoinflammatory syndrome. Available at http://www.orpha.net/ data/patho/Pro/en/FamilialColdUrticaria-FRen-Pro10608. pdf. Accessed January 29, 2009.
16. Hoffman, H.M., F.A. Wright, D.H. Broide, et al. 2000. Identification of a locus on chromosome 1q44 for familial cold urticaria. Am. J. Hum. Genet. 66: 1693-1698.
17. Hoffman, H.M. 2009. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin. Biol. Ther. 9: 519-531.
18. Martinon, F., K. Burns & J. Tschopp. 2002. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 10: 417-426.
19. Kanneganti, T.D., N. Ozoren, M. Body-Malapel, et al. 2006. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440: 233-236.
20. Mariathasan, S., D.S. Weiss, K. Newton, et al. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
21. Hawkins, P.N., H.J. Lachmann & M.F. McDermott. 2003. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348: 2583-2584.
22. Goldbach-Mansky, R., N.J. Dailey, S.W. Canna, et al. 2006. Neonatal-onsetmultisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355: 581-592.
23. Hoffman, H.M., S. Rosengren, D.L. Boyle, et al. 2004. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364: 1779-1785.
24. Goldbach-Mansky, R., S.D. Shroff, M. Wilson, et al. 2008. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 58: 2432-2442.
25. US Department of Health andHuman Services Food andDrug Administration. 2006. Guidance for Industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. Center for Drugs Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Rockville, MD.
26. Hoffman, H.M., F.Wolfe, P. Belomestnov, et al. 2008. Cryopyrin-associated periodic syndromes: Development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr. Med. Res. Opin. 24: 2531-2543.
27. Hoffman, H.M., M.L. Throne, N.J. Amar, et al. 2008. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebocontrolled studies. Arthritis Rheum. 58: 2443-2452.
28. Cartwright, R., M. Throne, D. Nadler, et al. 2009. Rilonacept (IL-1 Trap) results in rapid and sustained reduction of clinical symptoms in patients with cryopyrin-associated periodic syndromes (CAPS) [abstract]. Cytokine Therapies: Novel Approaches to Clinical Indications. New York, NY. March 26-27, 2009.
29. Hoffman, H.M., N.J. Amar, R.C. Cartwright, et al. 2008. Durability of response to rilonacept (IL-1 Trap) in a phase 3 study of patients with cryopryinassociated periodic syndromes (CAPS): Familial cold autinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS) [abstract]. Annual Congress of the European League Against Rheumatism. Paris, France. June 11-14, 2008. Ann. Rheum Dis. 67(Suppl II):104.
30. Hoffman, H.M., D. Nadler, M. Mahony, et al. 2009. Durability of response to rilonacept (IL-1 Trap): Long-term follow-up in patients with cryopyrinassociated periodic syndromes (CAPS) [abstract]. Annual Congress of the European League Against Rheumatism. Copenhagen, Denmark. June 10-13, 2009. Ann. Rheum Dis. 68(Suppl 3):197.
31. Torri, A., P. Belomestnov, N. Stahl, et al. 2009. The use of IL-1b levels as a marker for IL-1 driven diseases: Comparison of IL-1b expression levels in patients with rheumatoid arthritis (RA), cryopyrinassociated periodic syndromes (CAPS) and gout [abstract]. Annual Congress of the European League Against Rheumatism. Copenhagen, Denmark. June 10-13, 2009. Ann. Rheum Dis. 68(Suppl 3):189.
32. Martinon, F., V. Petrilli, A. Mayor, et al. 2006. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241.
33. Chen, C.J., Y. Shi, A. Hearn, et al. 2006. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated bymonosodium urate crystals. J. Clin. Invest. 116: 2262-2271.
34. So, A., T. De Smedt, S. Revaz, et al. 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9: R28.
35. Torres, R., K. Macdonald, J. Reinhardt, et al. 2009. Pain and inflammation in animal models of gout is reduced by m-IL-1 Trap [abstract]. Cytokine Therapies: Novel Approaches to Clinical Indications. New York, NY. March 26-27, 2009.
36. Terkeltaub, R., J. Sundy, H.R. Schumacher, et al. 2009. The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of placebo-controlled, cross-over pilot study. Ann. Rheum. Dis. 68: 1613-1617.
37. Sarawate, C.A., K.K. Brewer, W. Yang, et al. 2006. Gout medication treatment patterns and adherence to standards of care froma managed care perspective. Mayo Clin. Proc. 81: 925-934.
38. Knapp, H.R., H.R. Schumacher, J.S. Sundy, et al. 2009. Rilonacept reduces the occurrence of gout flares that may be precipitated by initiation of uratelowering therapy [abstract]. Cytokine Therapies: Novel Approaches to Clinical Indications. New York, NY. March 26-27, 2009.
39. Schumacher, H.R., J.S. Sundy, R. Terkeltaub, et al. 2009. Placebo-controlled study of rilonacept for prevention of gout flares during initiation of uratelowering therapy [abstract]. Annual Congress of the European League Against Rheumatism. Copenhagen, Denmark. June 10-13, 2009. Ann. Rheum Dis. 68(Suppl 3):680.